Editor: Todd B. Reynolds, University of Tennessee, UNITED STATES mycetoma [14] , most mycoses still demand attention from public health authorities and decision makers. Funding for fungal diseases is incredibly small compared to funding available for infectious diseases causing similar mortality (Fig 1 and [15] ). Mycetoma, chromoblastomycosis, and "other deep mycoses" have been recently included in the World Health Organization (WHO)'s list of neglected tropical diseases, but specific information on WHO's plans to fight fungal diseases is still not publicly available [16] . Cryptococcal meningitis, which ranks amongst the most poorly funded diseases in the world, has recently been proposed as a neglected tropical disease [17] .
Funding for fungal diseases
The current scenario is incompatible with an optimistic perspective, as illustrated by the most recent edition of the Global Funding of Innovation for Neglected Diseases (G-Finder) Report [18] . Cryptococcal meningitis was the only fungal disease with measurable funding mentioned in the report. Other fungal diseases were not included in the report, denoting negligible funding. This is consistent with earlier estimates for research and development funding for human data collection and analysis, decision to publish, or preparation of the manuscript.
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cryptococcosis that revealed indices of support that were greatly disproportionate to its importance for global health in comparison to other neglected diseases [15] . Cryptococcosis was classified within the most poorly funded neglected diseases covered by the G-Finder survey, receiving less than 0.5% of global funding [18] . According to statistics obtained from WHO's public databases, cryptococcal meningitis is the fourth most deadly infectious disease (excluding HIV), after tuberculosis (approximately 1,700,000 deaths [19] ), diarrheal diseases (approximately 525,000 deaths [20] ), and malaria (approximately 438,000 deaths [21] ). However, according to the 2017 G-Finder report [18] , scientific activities in the field of cryptococcal meningitis received approximately 100-fold reduced funding in comparison to malaria and tuberculosis and 25-fold reduced funding in comparison to diarrheal diseases. For a more direct disease comparison, cryptococcal meningitis kills 20 times more humans than the brain disease caused by the bacterial pathogen Neisseria meningitidis [22] . Nevertheless, funding for research on bacterial meningitis was 4.35-fold higher than that available for the fungal disease (Fig 1 and [18] ).
Other clinically relevant but neglected mycoses, including paracoccidioidomycosis, mycetoma, sporotrichosis, and chromoblastomycosis, were not even mentioned in the G-Finder report [18] , suggesting that these areas of research received negligible funding. We used publication data (2017) from the Web of Science database (https://clarivate.com/products/webofscience/databases/) to probe the impact of this lack of funding. For comparison, we included tuberculosis and malaria, for which well-established programs of funding are available [18] . We found that tuberculosis and malaria were the focus of 8,827 and 5,687 articles published in 2017, respectively. In contrast, fungal diseases were much less investigated, producing 213 (cryptococcosis), 80 (paracoccidioidomycosis), 51 (chromoblastomycosis), 53 (mycetoma), and 56 (sporotrichosis) articles in the same period (Table 1) .
We further examined the authors' statements of financial support for major international agencies with a history of support of research into neglected diseases [23] , such as the National Institutes of Health, USA, the Bill and Melinda Gates Foundation, the National Natural Science Foundation of China, the Wellcome Trust, the Medical Research Council, the European Commission, and the European Research Council. We found that 22.5% to 31% of the articles published in the fields of cryptococcosis, malaria, and tuberculosis received financial support from at least one major funding organization, corresponding to 2,245 articles in the field of tuberculosis, 1,765 articles in the field of malaria, and only 48 articles in the area of cryptococcosis. In the chromoblastomycosis field, 13.7% of the studies reported major financial support, with the particularity that all these articles (n = 7) received funding from the National Natural Science Foundation of China. The general picture was more serious in the fields of paracoccidioidomycosis, sporotrichosis, and mycetoma. Funding from major organizations was reported in only six articles focused on paracoccidioidomycosis (7.5%) and four publications in the area of sporotrichosis (7.1%). Only one article reported support from major funding agencies in the field of mycetoma (1.9%). These results are all summarized in Table 1 .
Time for action
Health emergencies such as the recent Zika outbreak demand rapid responses [24] , but responses are similarly necessary to combat diseases that have been devastating different nations for years. Recently, there have been numerous calls for change in the current scenario of research, development, innovation, and public health in the field of fungal diseases [3, 9, 15, 17, [25] [26] [27] . We recognize that changes of this magnitude are complex and hard to achieve, especially in times of crisis involving economic and public health issues [28] . For fungal diseases, the need for change is unquestionable: it is time for action. 
